Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Instil Bio

Request full access

Clinical-stage immuno-oncology company focused on developing patient specific immunotherapy

Dallas, United StatesFounded 2008Biotech & Life Sciences

About Instil Bio

Instil Bio, Inc. operates as a clinical-stage biopharmaceutical company, directing its efforts toward the development of cell therapies for the treatment of cancer. The company was incorporated in 2018 and is headquartered in Dallas, Texas. The foundation of Instil Bio's therapeutic approach is built upon tumor-infiltrating lymphocytes (TILs), a type of cancer immunotherapy. This involves harvesting a patient's own T cells that have infiltrated their tumor, expanding them to large numbers in a laboratory setting, and then infusing them back into the patient to attack the cancer. The company's lead product candidate is ITIL-168, which has been evaluated in a Phase 2 clinical trial for the treatment of advanced melanoma. Another product, ITIL-306, is in a Phase 1 trial for non-small cell lung cancer, ovarian cancer, and head and neck squamous cell carcinoma. Instil Bio's business model centers on the in-licensing, acquisition, and subsequent development of these novel therapeutic candidates to address significant unmet medical needs in oncology. The company has positioned itself in the competitive immuno-oncology market, targeting solid tumors, which represent a substantial area of need. Significant milestones for the company include its initial public offering (IPO) in March 2021, which raised approximately $368 million. This event provided substantial capital to advance its clinical pipeline. However, the company has faced challenges. In late 2022, Instil Bio announced a significant restructuring, which included pausing the development of its ITIL-168 program to extend its cash runway and discontinuing its phase 1 trial of ITIL-306. This strategic shift also involved a substantial reduction in its workforce as the company refocused its resources. As of early 2024, the company's focus remained on a strategic reprioritization of its pipeline and manufacturing operations.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2021

Instil Bio in the Dallas ecosystem

Live from Dealroom

The Instil Bio office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

1 investor on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later1 investor entered at this stage

  • The University of Manchester
Team profiled 15 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Patents

Estimated portfolio value
$4M

22 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

See Instil Bio on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.